Depression and Associated Factors Among the Elderly Population in an Urban Tertiary Geriatric Hospital in Bangladesh. Reviewed

Tabassum T, Suzuki T, Iwata Y, Ishiguro H

Gerontol Geriatr Med   2023

Psychological distress among early medical residents: A 2-year longitudinal cohort study over seven years in Japan. Reviewed

Watanabe S, Uemura T, Iwata Y, Yagasaki H, Itakura J, Suzuki T.

Comprehensive Psychiatry   2023

Destructive thyroiditis associated with lithium use: A case report and review of the literature. Reviewed

Uemura T, Kobayashi K, Uchinuma N, Shioe R, Hirata T, Suzuki T.

Psychiatry Research Case Reports.   2023

Predictors of response to pharmacotherapy in children and adolescents with psychiatric disorders: A combined post hoc analysis of four clinical trial data. Reviewed

Tsujii T, Sakurai H, Takeuchi H, Suzuki T, Mimura M, Uchida H.

Neuropsychopharmacol Rep.   2022.11

A 93-year-old patient with major depressive disorder successfully treated with electroconvulsive therapy: A case report and review of the literature: Electroconvulsive therapy in a 93 y.o. patient. Reviewed

Tada Teruo, Yasuda Kazuyuki, Watanabe Shintaro, Ishibashi Akifumi, Watanabe Koichiro, Suzuki Takefumi.

Psychiatry Research Case Reports.   2022.6

Electroconvulsive Therapy in a Patient With Depression on Hemodialysis: A Review of the Literature. Reviewed

Watanabe S, Yasuda K, Tada T, Ishibashi A, Suzuki T.

J ECT.   2022.5

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. Reviewed

Wada M, Noda Y, Iwata Y, Tsugawa S, Yoshida K, Tani H, Hirano Y, Koike S, Sasabayashi D, Katayama H, Plitman E, Ohi K, Ueno F, Caravaggio F, Koizumi T, Gerretsen P, Suzuki T, Uchida H, Müller DJ, Mimura M, Remington G, Grace AA, Graff-Guerrero A, Nakajima S.

Mol Psychiatry   2022.4

Catheter-related bloodstream infection in patients With severe anorexia nervosa. Reviewed

Hirata T, Yasuda K, Iwata Y, Uemura T, Aruga Y, Shioe R, Uchinuma N, Tamaoki T, Suzuki T.

PERSPECTIVES IN PSYCHIATRIC CARE   2022.2( ISSN：0031-5990 )

MAP Bayesian modeling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. Reviewed

Ismail M, Straubinger T, Uchida H, Graff-Guerrero A, Nakajima S, Suzuki T, Caravaggio F, Gerretsen P, Mamo D, Mulsant BH, Pollock BG, Bies R.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY   2022.2( ISSN：0306-5251 )

Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. Reviewed

Kusudo K, Ochi R, Nakajima S, Suzuki T, Mamo D, Caravaggio F, Mar W, Gerretsen P, Mimura M, Pollock BG, Mulsant BH, Graff-Guerrero A, Rajji TK, Uchida H.

SCHIZOPHRENIA RESEARCH   2022.2( ISSN：0920-9964 )

Cancellation of outpatient appointments in patients with attention-deficit/hyperactivity disorder. Reviewed

Nomura K, Tarumi R, Yoshida K, Sado M, Suzuki T, Mimura M, Uchida H.

PLoS One   2021.11( ISSN：1932-6203 )

Comorbid Psychiatric Disorders in Patients Hospitalized for Pulmonary Embolism and Acute Myocardial Infarction: A Japanese Nationwide Database Study. Reviewed

Takahashi K, Uchida H, Suzuki T, Mimura M, Ishida T.

JOURNAL OF CLINICAL PSYCHIATRY   2021.11( ISSN：0160-6689 )

Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series. Reviewed

Tani H, Tomita M, Suzuki T, Mimura M, Uchida H.

Clinical Psychopharmacology and Neuroscience   2021.11( ISSN：1738-1088 )

Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms. Reviewed

Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H.

SCHIZOPHRENIA RESEARCH   2021.9( ISSN：0920-9964 )

Development of a risk stratification scoring system for deep vein thrombosis upon psychiatric admission. Reviewed

Ishida T, Shibahashi K, Sugai S, Abe D, Hamabe Y, Kashiyama T, Mimura M, Suzuki T, Uchida H.

JOURNAL OF PSYCHOSOMATIC RESEARCH   2021.5( ISSN：0022-3999 )

Prescription patterns in patients with schizophrenia who discontinued long-acting injectable antipsychotics: a chart-review. Reviewed

Asano K, Suzuki T, Mimura M, Uchida H.

PSYCHIATRY AND CLINICAL NEUROSCIENCES   2021.3( ISSN：1323-1316 )

Successful Introduction of Paliperidone Palmitate for Pregnant Woman With Schizophrenia: Case Presentation and Literature Review. Reviewed

Iwata Y, Aruga Y, Ohtsuki M, Inoue M, Yasuda K, Hirata T, Uemura T, Suzuki T.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY   2021.3( ISSN：0271-0749 )

Pre-existing psychiatric disorder is related to lower mortality from road traffic accident: A Japanese nationwide retrospective cohort study. Reviewed

Ishida T, Kuwahara Y, Shibahashi K, Okura Y, Sugiyama K, Yoshimura K, Hamabe Y, Mimura M, Suzuki T, Uchida H.

INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED   2021.2( ISSN：0020-1383 )

Single Versus Multiple Daily Dosing Regimens of Psychotropic Drugs for Psychiatric Disorders: A Systematic Review and Meta-Analysis. Reviewed

Kikuchi Y, Shimomura Y, Suzuki T, Uchida H, Mimura M, Takeuchi H.

JOURNAL OF CLINICAL PSYCHIATRY   2021.2( ISSN：0160-6689 )

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Reviewed

Sakurai H, Yasui-Furukori N, Suzuki T, Uchida H, Baba H, Watanabe K, Inada K, Kikuchi YS, Kikuchi T, Katsuki A, Kishida I, Kato M.

PHARMACOPSYCHIATRY   2021.1( ISSN：0176-3679 )

Flumazenil for Successful Seizure Induction With Electroconvulsive Therapy: Case Report and Literature Review. Reviewed

Uchinuma N, Yasuda K, Iwata Y, Hirata T, Uemura T, Tamaoki T, Suzuki T.

CLINICAL NEUROPHARMACOLOGY   2020( ISSN：0362-5664 )

How common is pulmonary embolism compared to acute myocardial infarction among patients with severe mental illnesses? Reviewed

Ishida T, Takahashi K, Sugiyama K, Hamabe Y, Mimura M, Suzuki T, Uchida H.

PSYCHIATRY AND CLINICAL NEUROSCIENCES   2020( ISSN：1323-1316 )

Pharmacological management of depression: Japanese expert consensus. Reviewed

Sakurai H, Uchida H, Kato M, Suzuki T, Baba H, Watanabe K, Inada K, Kikuchi T, Katsuki A, Kishida I, Sugawara Kikuchi Y, Yasui-Furukori N; Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology.

JOURNAL OF AFFECTIVE DISORDERS   2020( ISSN：0165-0327 )

Life-Threatening Serotonin Syndrome Precipitated by Discontinuation of Serotonin-Dopamine Antagonist in the Presence of Serotonergic Agents: A Case Report. Reviewed

Ishida T, Uchida H, Kaneko S, Sugiyama K, Hamabe Y, Mimura M, Suzuki T.

CLINICAL NEUROPHARMACOLOGY   2020( ISSN：0362-5664 )

Drug Attitude, Insight, and Patient's Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey. Reviewed

Nagai N, Tani H, Yoshida K, Gerretsen P, Suzuki T, Ikai-Tani S, Mimura M, Uchida H.

Neuropsychiatric Disease and Treatment   2020

Factors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI). Reviewed

Tsuboi T, Suzuki T, Azekawa T, Adachi N, Ueda H, Edagawa K, Katsumoto E, Kubota Y, Goto E, Hongo S, Watanabe Y, Kato M, Yasui-Furukori N, Yoshimura R, Nakagawa A, Kikuchi T, Watanabe K.

Neuropsychiatric Disease and Treatment   2020

Electroconvulsive therapy in patients with cerebral aneurysms taking an anticoagulant or antiplatelet-report on three cases and review of the literature. Reviewed

Hirata T, Yasuda K, Uemura T, Ueda T, Aruga Y, Shioe R, Tamaoki T, Suzuki T.

PSYCHIATRY RESEARCH   2020( ISSN：0165-1781 )

Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study. Reviewed

Takahashi K, Yamazawa R, Suzuki T, Mimura M, Uchida H.

Neuropsychopharmacol Rep.   2020

Pharmacological Management of Bipolar Disorder: Japanese Expert Consensus. Reviewed

Sakurai H, Kato M, Yasui-Furukori N, Suzuki T, Baba H, Watanabe K, Inada K, Kishida I, Sugawara Kikuchi Y, Kikuchi T, Katsuki A, Uchida H; Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology.

BIPOLAR DISORDERS   2020( ISSN：1398-5647 )

Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. Reviewed

Kurose S, Mimura Y, Uchida H, Takahata K, Kim E, Suzuki T, Mimura M, Takeuchi H.

JOURNAL OF CLINICAL PSYCHIATRY   2020( ISSN：0160-6689 )

Lower mortality from suicidal trauma among patients with a psychiatric diagnosis upon admission: Nationwide japanese retrospective cohort study. Reviewed

Ishida T, Kuwahara Y, Shibahashi K, Okura Y, Sugiyama K, Hamabe Y, Mimura M, Suzuki T, Uchida H.

PSYCHIATRY RESEARCH   2020( ISSN：0165-1781 )

Factors Associated With Delirium Following Electroconvulsive Therapy: A Systematic Review

Tsujii T, Uchida T, Suzuki T, Mimura M, Hirano J, Uchida H.

JOURNAL OF ECT   2019.12( ISSN：1095-0680 )

Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. Reviewed

Shimomura Y, Kikuchi Y, Suzuki T, Uchida H, Mimura M, Takeuchi H.

SCHIZOPHRENIA RESEARCH   2019( ISSN：0920-9964 )

Concomitant use of alcohol and benzodiazepine hypnotics in psychiatric outpatients: a cross-sectional survey. Reviewed

Uchida T, Hirano J, Sakurai H, Suzuki T, Mimura M, Uchida H.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY   2019( ISSN：0268-1315 )

Alteration in AMPA receptor subunit expression and receptor binding among patients with addictive disorders: A systematic review of human postmortem studies. Reviewed

Ueno F, Suzuki T, Nakajima S, Matsushita S, Mimura M, Miyazaki T, Takahashi T, Uchida H.

Neuropsychopharmacol Rep.   2019

Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial. Reviewed

Ozawa C, Bies RR, Pillai N, Suzuki T, Mimura M, Uchida H.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY   2019( ISSN：0271-0749 )

Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. Reviewed

Koizumi T, Suzuki T, Pillai NS, Bies RR, Takeuchi H, Yoshimura K, Mimura M, Uchida H.

JOURNAL OF PSYCHIATRIC RESEARCH   2019( ISSN：0022-3956 )

Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Reviewed

Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY   2019( ISSN：0268-1315 )

Antipsychotic serious adverse events in context. Reviewed

Suzuki T.

Lancet Psychiatry   2019( ISSN：2215-0374 )

Transvestism Recognized in Ehlers-Danlos Syndrome: Report of Two Cases. Reviewed

Ishiguro H, Honobe N, Suzuki T, Tamai M, Nakane T.

Case Rep Psychiatry.   2019

Lower Proportion of Fatal Arrhythmia in Sudden Cardiac Arrest Among Patients With Severe Mental Illness Than Nonpsychiatric Patients. Reviewed

Ishida T, Sugiyama K, Tanabe T, Hamabe Y, Mimura M, Suzuki T, Uchida H.

PSYCHOSOMATICS   2019( ISSN：0033-3182 )

Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial. Reviewed

Saito Y, Sakurai H, Kane JM, Schooler NR, Suzuki T, Mimura M, Uchida H.

SCHIZOPHRENIA RESEARCH   2019( ISSN：0920-9964 )

Factors Associated With Delirium Following Electroconvulsive Therapy: A Systematic Review.

Tsujii T, Uchida T, Suzuki T, Mimura M, Hirano J, Uchida H.

JOURNAL OF ECT   2019( ISSN：1095-0680 )

Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. Reviewed

Tani H, Takasu S, Uchida H, Suzuki T, Mimura M, Takeuchi H

NEUROPSYCHOPHARMACOLOGY   2019( ISSN：0893-133X )

Etiologies of out-of-hospital cardiac arrest among psychiatric patients: a chart review. Reviewed

Ishida T, Miyazaki K, Yukawa T, Yamagishi T, Sugiyama K, Tanabe T, Hamabe Y, Mimura M, Suzuki T, Uchida H.

PSYCHIATRY AND CLINICAL NEUROSCIENCES   2018( ISSN：1323-1316 )

Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross-sectional study. Reviewed

Mizuno Y, Hofer A, Frajo-Apor B, Wartelsteiner F, Kemmler G, Pardeller S, Suzuki T, Mimura M, Fleischhacker WW, Uchida H.

Acta Psychiatr Scand. 2017 Nov 15. doi: 10.1111/acps.12838. [Epub ahead of print]   2018

Subtyping Schizophrenia by Social Functioning - a Pragmatic Proposal for Clinics and Research Reviewed

Suzuki T

Psychiatr Q. 2018 Jan 3. doi: 10.1007/s11126-017-9558-z. [Epub ahead of print]   2018

A Possible Role of Takotsubo Cardiomyopathy in Ventricular Fibrillation During Delirium Tremens: A Case Report and Literature Review. Reviewed

Ishida T, Uchida H, Miyazaki K, Yukawa T, Sugiyama K, Hamabe Y, Mimura M, Suzuki T.

Psychosomatics. 2017 Nov 24. pii: S0033-3182(17)30228-1. doi: 10.1016/j.psym.2017.11.008. [Epub ahead of print]   2018

Discrepancies Between Nomenclature and Indications of Psychotropics. Reviewed

Minami F, Zohar J, Suzuki T, Koizumi T, Mimura M, Yagi G, Uchida H.

PHARMACOPSYCHIATRY   2018( ISSN：0176-3679 )

Kampo, A Japanese Traditional Medicinal System for Psychiatric Conditions: A Narrative Review. Reviewed

Tatsumi L, Suzuki T, Yamada K, Mimura M, Uchida H.

PHARMACOPSYCHIATRY   2018( ISSN：0176-3679 )

Psychopharmacology in Japan: An Overview and Recent Topics. Reviewed

Yoshida K, Suzuki T, Uchida H.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY   2018( ISSN：0271-0749 )

Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs. Reviewed

Kubo K, Fleischhacker WW, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H.

ACTA PSYCHIATRICA SCANDINAVICA   2018( ISSN：0001-690X )

Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics: A Literature Review. Reviewed

Tani H, Suzuki T, Wolfgang Fleischhacker W, Tomita M, Mimura M, Uchida H.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY   2018( ISSN：0271-0749 )

Mood stabilizers as an Achilles' heel for indication-based nomenclature and roles of Neuroscience-based Nomenclature. Reviewed

Kikuchi Y, Zohar J, Suzuki T, Mimura M, Yagi G, Uchida H.

PSYCHIATRY AND CLINICAL NEUROSCIENCES   2018( ISSN：1323-1316 )

Electroconvulsive Therapy While Receiving Oral Anticoagulation for Deep Venous Thrombosis: Report on Eight Cases and a Review of the Literature. Reviewed

Hirata T, Yasuda K, Uemura T, Ohtsuki M, Kobayashi K, Ueda T, Aruga Y, Tamaoki T, Suzuki T.

PSYCHOSOMATICS   2018( ISSN：0033-3182 )

Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs. Reviewed

Kumagai F, Suzuki T, Fleischhacker WW, Yasui-Furukori N, Mimura M, Uchida H.

JOURNAL OF CLINICAL PSYCHIATRY   2018( ISSN：0160-6689 )

Mortality from sepsis among patients with schizophrenia and mood disorders in an intensive care unit: A chart review. Reviewed

Ishida T, Nakamura K, Miyazaki K, Yukawa T, Yamagishi T, Sugiyama K, Tanabe T, Hamabe Y, Mimura M, Suzuki T, Uchida H.

PSYCHIATRY RESEARCH   2018( ISSN：0165-1781 )

Impact of subjective vs. objective remission status on subjective cognitive impairments in depression. Reviewed

Sawada K, Yoshida K, Ozawa C, Mizuno Y, Rubinstein EB, Suzuki T, Mimura M, Uchida H.

JOURNAL OF AFFECTIVE DISORDERS   2018( ISSN：0165-0327 )

Effect of Clozapine vs Other Second-Generation Antipsychotics on Hospitalization and Seclusion: A Retrospective Mirror-Image Study in a Japanese Public Psychiatric Hospital. Reviewed

Misawa F, Suzuki T, Fujii Y.

J Clin Psychopharmacol. 2017 Dec;37(6):664-668. doi: 10.1097/JCP.0000000000000798.   2017.12

Effects of chair yoga therapy on physical fitness in patients with psychiatric disorders: A 12-week single-blind randomized controlled trial. Reviewed

Ikai S, Uchida H, Mizuno Y, Tani H, Nagaoka M, Tsunoda K, Mimura M, Suzuki T.

J Psychiatr Res. 2017 Nov;94:194-201. doi: 10.1016/j.jpsychires.2017.07.015.   2017.11

Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey. Reviewed

Nagai N, Tani H, Suzuki T, Ikai S, Gerretsen P, Mimura M, Uchida H.

Pharmacopsychiatry. 2017 Nov;50(6):264-269. doi: 10.1055/s-0043-113828.   2017.11

Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. Reviewed

Hofer A, Mizuno Y, Wartelsteiner F, Wolfgang Fleischhacker W, Frajo-Apor B, Kemmler G, Mimura M, Pardeller S, Sondermann C, Suzuki T, Welte A, Uchida H.

Eur Psychiatry. 2017 Oct;46:42-47. doi: 10.1016/j.eurpsy.2017.08.005.   2017.10

Psychotic Symptoms Associated With Varenicline in a Patient With Alcohol and Nicotine Dependence: A Case Report. Reviewed

Ueno F, Uchida H, Suzuki T, Yokoyama A, Matsushita S, Mimura M, Higuchi S.

J Clin Psychopharmacol. 2017 Oct;37(5):627-628. doi: 10.1097/JCP.0000000000000771.   2017.10

Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study. Reviewed

Kitahata R, Nakajima S, Uchida H, Hayashida T, Takahashi M, Nio S, Hirano J, Nagaoka M, Suzuki T, Jinno H, Kitagawa Y, Mimura M.

Neuropsychiatr Dis Treat. 2017 Oct 3;13:2489-2496. doi: 10.2147/NDT.S141408. eCollection 2017.   2017.10

Resilience and spirituality in patients with depression and their family members: A cross-sectional study. Reviewed

Ozawa C, Suzuki T, Mizuno Y, Tarumi R, Yoshida K, Fujii K, Hirano J, Tani H, Rubinstein EB, Mimura M, Uchida H.

Compr Psychiatry. 2017 Aug;77:53-59. doi: 10.1016/j.comppsych.2017.06.002.   2017.8

Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. Reviewed

Sakurai H, Suzuki T, Yoshimura K, Mimura M, Uchida H.

Psychopharmacology (Berl). 2017 Aug;234(16):2453-2461. doi: 10.1007/s00213-017-4634-5.   2017.8

Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. Reviewed

Yoshida K, Roberts R, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

Am J Geriatr Psychiatry. 2017 Jul;25(7):708-716. doi: 10.1016/j.jagp.2017.01.016.   2017.7

Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. Reviewed

Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G.

Schizophr Bull. 2017 Jul 1;43(4):862-871. doi: 10.1093/schbul/sbw171.   2017.7

Kirino S, Suzuki T, Takeuchi H, Mimura M, Uchida H. Reviewed

Representativeness of clinical PET study participants with schizophrenia: A systematic review.

J Psychiatr Res. 2017 May;88:72-79. doi: 10.1016/j.jpsychires.2016.12.023.   2017.5

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Reviewed

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, Bloomfield MA, Bressan RA, Buchanan RW, Carpenter WT, Castle DJ, Citrome L, Daskalakis ZJ, Davidson M, Drake RJ, Dursun S, Ebdrup BH, Elkis H, Falkai P, Fleischacker WW, Gadelha A, Gaughran F, Glenthøj BY, Graff-Guerrero A, Hallak JE, Honer WG, Kennedy J, Kinon BJ, Lawrie SM, Lee J, Leweke FM, MacCabe JH, McNabb CB, Meltzer H, Möller HJ, Nakajima S, Pantelis C, Reis Marques T, Remington G, Rossell SL, Russell BR, Siu CO, Suzuki T, Sommer IE, Taylor D, Thomas N, Üçok A, Umbricht D, Walters JT, Kane J, Correll CU.

Am J Psychiatry. 2017 Mar 1;174(3):216-229. doi: 10.1176/appi.ajp.2016.16050503.   2017.3

Early Improvement of Specific Symptoms Predicts Subsequent Recovery in Bipolar Depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Data. Reviewed

Mizushima J, Uchida H, Tada M, Suzuki T, Mimura M, Nio S.

J Clin Psychiatry. 2017 Feb;78(2):e146-e151. doi: 10.4088/JCP.15m10573.   2017.2

Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. Reviewed

Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC, Graff-Guerrero A.

Am J Geriatr Psychiatry. 2017 Jan;25(1):1-10. doi: 10.1016/j.jagp.2016.08.001.   2017.1

Psychological dependence on antidepressants in patients with panic disorder: a cross-sectional study. Reviewed

Fujii K, Suzuki T, Mimura M, Uchida H.

Int Clin Psychopharmacol. 2017 Jan;32(1):36-40.   2017.1

Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data. Reviewed

Ozawa C, Roberts R, Yoshida K, Suzuki T, Lebowitz B, Reeves S, Howard R, Abe T, Mimura M, Uchida H.

J Clin Psychiatry. 2017 Nov/Dec;78(9):e1204-e1210. doi: 10.4088/JCP.17m11461.   2017

Prediction Model of Serum Lithium Concentrations. Reviewed

Yoshida K, Uchida H, Suzuki T, Watanabe M, Yoshino N, Houchi H, Mimura M, Fukuoka N.

Pharmacopsychiatry. 2017 Aug 2. doi: 10.1055/s-0043-116855. [Epub ahead of print]   2017

Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. Reviewed

Iwata Y, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Plitman E, Chung JK, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Rajji TK, Mamo DC, Graff-Guerrero A.

J Clin Psychiatry. 2016 Dec;77(12):e1557-e1563. doi: 10.4088/JCP.15m10538.   2016.12

Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study. Reviewed

Ikai S, Suzuki T, Mimura M, Uchida H.

Psychopharmacology (Berl). 2016 Dec;233(23-24):4003-4010.   2016.12

Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial. Reviewed

Sakurai H, Suzuki T, Bies RR, Pollock BG, Mimura M, Kapur S, Uchida H.

J Clin Psychiatry. 2016 Oct;77(10):1381-1390. doi: 10.4088/JCP.15m10490.   2016.10

Prescription patterns for depression among consultation-liaison psychiatrists and non-psychiatrists: a chart review. Reviewed

Ikai S, Suzuki T, Uchida H, Saito H, Mimura M, Takeuchi H.

Int J Geriatr Psychiatry. 2016 Sep;31(9):1084-5. doi: 10.1002/gps.4341.   2016.9

Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated with Mirtazapine. Reviewed

Funaki K, Nakajima S, Suzuki T, Mimura M, Uchida H.

J Clin Pharmacol. 2016 Sep;56(9):1111-9. doi: 10.1002/jcph.710.   2016.9

Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. Reviewed

Mizuno Y, Hofer A, Suzuki T, Frajo-Apor B, Wartelsteiner F, Kemmler G, Saruta J, Tsukinoki K, Mimura M, Fleischhacker WW, Uchida H.

Schizophr Res. 2016 Aug;175(1-3):148-153. doi: 10.1016/j.schres.2016.04.047.   2016.8

Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: Cultural comparison in Austria and Japan. Reviewed

Hofer A, Mizuno Y, Frajo-Apor B, Kemmler G, Suzuki T, Pardeller S, Welte AS, Sondermann C, Mimura M, Wartelsteiner F, Fleischhacker WW, Uchida H.

Schizophr Res. 2016 Mar;171(1-3):86-91. doi: 10.1016/j.schres.2016.01.027.   2016.3

Resilience in schizophrenia: A comparative study between a remote island and an urban area in Japan Reviewed

Yoshida K, Suzuki T, Imasaka Y, Kubo KI, Mizuno Y, Saruta J, Tsukinoki K, Mimura M, Uchida H.

Schizophr Res. 2016 Mar;171(1-3):92-6. doi: 10.1016/j.schres.2016.01.030.   2016.3

Postural sway and flexibility in patients with schizophrenia-spectrum disorders: A cross-sectional study. Reviewed

Ikai S, Uchida H, Suzuki T, Tsunoda K, Fujii Y, Mimura M.

Asian J Psychiatr. 2016 Feb;19:14-8. doi: 10.1016/j.ajp.2015.11.008.   2016.2

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. Reviewed

Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A.

Schizophr Bull. 2016 Jan;42(1):212-9. doi: 10.1093/schbul/sbv106.   2016.1

A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal Reviewed

Suzuki T

Expert Opin Drug Deliv. 2016;13(2):253-64. doi: 10.1517/17425247.2016.1115479.   2016

Relapse of ileus in patients with psychiatric disorders: A 2-year chart review. Reviewed

Kitahata R, Nakajima S, Suzuki T, Plitman E, Mimura M, Uchida H.

Gen Hosp Psychiatry. 2016 Jan-Feb;38:31-6. doi: 10.1016/j.genhosppsych.2015.09.003.   2016

Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. Reviewed

Tsuboi T, Bies RR, Suzuki T, Takeuchi H, Nakajima S, Graff-Guerrero A, Mamo DC, Caravaggio F, Plitman E, Mimura M, Pollock BG, Uchida H.

Pharmacopsychiatry. 2015 Nov;48(7):286-91. doi: 10.1055/s-0035-1565070.   2015.11

Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Reviewed

Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H.

Mol Psychiatry. 2015 Oct;20(10):1151-60. doi: 10.1038/mp.2015.68.   2015.10

Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data. Reviewed

Tada M, Uchida H, Mizushima J, Suzuki T, Mimura M, Nio S.

J Psychiatr Res. 2015 Sep;68:151-6. doi: 10.1016/j.jpsychires.2015.06.015.   2015.9

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study. Reviewed

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.

JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891.   2015.9

Language Barriers and Access to Psychiatric Care: A Systematic Review. Reviewed

Ohtani A, Suzuki T, Takeuchi H, Uchida H.

Psychiatr Serv. 2015 Aug 1;66(8):798-805. doi: 10.1176/appi.ps.201400351.   2015.8

Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year. Reviewed

Suzuki T, Uchida H, Takeuchi H, Tsunoda K, Ishizuki T, Mimura M.

Psychiatry Res. 2015 Jul 30;228(1):26-30. doi: 10.1016/j.psychres.2015.03.019.   2015.7

A questionnaire survey of Japanese non-psychiatrists' attitudes on management of depression in a general hospital. Reviewed

Ikai S, Suzuki T, Uchida H, Saito H, Mimura M, Takeuchi H.

Asian J Psychiatr. 2015 Jun;15:73-4. doi: 10.1016/j.ajp.2015.04.003.   2015.6

Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. Reviewed

Suzuki T, Uchida H, Sakurai H, Ishizuki T, Tsunoda K, Takeuchi H, Mimura M.

Psychiatry Res. 2015 Jun 30;227(2-3):265-9. doi: 10.1016/j.psychres.2015.02.024.   2015.6

Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. Reviewed

Takeuchi H, Suzuki T, Remington G, Uchida H.

Can J Psychiatry. 2015 May;60(5):215-22.   2015.5

Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [11C]-raclopride PET study. Reviewed

Nakajima S, Caravaggio F, Mamo DC, Mulsant BH, Chung JK, Plitman E, Iwata Y, Gerretsen P, Uchida H, Suzuki T, Mar W, Wilson AA, Houle S, Graff-Guerrero A.

Schizophr Res. 2015 May;164(1-3):263-7. doi: 10.1016/j.schres.2015.02.020.   2015.5

Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. Reviewed

Tsuboi T, Suzuki T, Bies RR, Remington G, Pollock BG, Mimura M, Uchida H.

Schizophr Res. 2015 May;164(1-3):149-54. doi: 10.1016/j.schres.2015.03.025.   2015.5

Cardiac Sudden Death in Psychiatric Patients.

Uchida H, Suzuki T.

Can J Psychiatry. 2015 May;60(5):203-5.   2015.5

Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression. Reviewed

Ueno F, Nakajima S, Suzuki T, Abe T, Sato Y, Mimura M, Uchida H.

J Clin Psychiatry. 2015 Apr;76(4):434-439. doi: 10.4088/JCP.14m09201.   2015.4

Dependence on Benzodiazepines in Patients with Panic Disorder: A Cross-Sectional Study. Reviewed

Fujii K, Uchida H, Suzuki T, Mimura M.

Psychiatry Clin Neurosci. 2015 Feb;69(2):93-9. doi: 10.1111/pcn.12203.   2015.2

Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. Reviewed

Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T, Rajji TK, Mamo DC.

Am J Geriatr Psychiatry. 2014 Oct;22(10):1007-16. doi: 10.1016/j.jagp.2013.01.045.   2014.12

Dose and Dosing Frequency of Long-Acting Injectable Antipsychotics: A Systematic Review of PET and SPECT Data and Clinical Implications. Reviewed

Uchida H, Suzuki T.

J Clin Psychopharmacol. 2014 Dec;34(6):728-35. doi: 10.1097/JCP.0000000000000065.   2014.12

Successful withdrawal from antipsychotic treatment in elderly male inpatients with schizophrenia-Description of four cases and review of the literature. Reviewed

Suzuki T, Uchida H.

Psychiatry Res. 2014 Dec 15;220(1-2):152-7. doi: 10.1016/j.psychres.2014.08.024.   2014.12

Ikai S, Suzuki T, Uchida H, Saruta J, Tsukinoki K, Fujii Y, Mimura M. Reviewed

Effects of Weekly One-Hour Hatha Yoga Therapy on Resilience and Stress Levels in Patients with Schizophrenia-Spectrum Disorders: An Eight-Week Randomized Controlled Trial.

J Altern Complement Med. 2014 Nov;20(11):823-30. doi: 10.1089/acm.2014.0205.   2014.11

Timing of Adjunctive Therapy in the Treatment of Depression: A Chart Review. Reviewed

Tarumi R, Suzuki T, Tani H, Den R, Sawada N, Sakurai H, Tsutsumi-Ozawa C, Ohtani A, Mimura M, Uchida H.

Pharmacopsychiatry. 2014 Nov;47(7):259-62. doi: 10.1055/s-0034-1387784.   2014.11

Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Reviewed

Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H.

Schizophr Bull. 2014 Nov;40(6):1385-403. doi: 10.1093/schbul/sbu030.   2014.11

Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study. Reviewed

Takeuchi H, Suzuki T, Bies RR, Remington G, Watanabe K, Mimura M, Uchida H.

J Clin Psychiatry. 2014 Nov;75(11):1209-14. doi: 10.4088/JCP.13m08841.   2014.11

Antipsychotic medications for schizophrenia.

Suzuki T.

JAMA. 2014 Oct 8;312(14):1468-9. doi: 10.1001/jama.2014.10103.   2014.10

A review on schizophrenia and relapse -a quest for user-friendly psychopharmacotherapy. Reviewed

Suzuki T, Uchida H, Takeuchi H, Tsuboi T, Hirano J, Mimura M.

Hum Psychopharmacol. 2014 Sep;29(5):414-26.   2014.9

Lack of Effect of Risperidone or Olanzapine Dose Reduction on Metabolic Parameters, Prolactin, and Corrected QT Interval in Stable Patients With Schizophrenia. Reviewed

Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H.

J Clin Psychopharmacol. 2014 Aug;34(4):517-20. doi: 10.1097/JCP.0000000000000142.   2014.8

Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Reviewed

Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H.

Psychiatry Res. 2014 Aug 15;218(1-2):244-6. doi: 10.1016/j.psychres.2014.04.019.   2014.8

Baseline Difference Between Patients' and Clinicians' Rated Illness Severity Scores and Subsequent Outcomes in Major Depressive Disorder: Analysis of the Sequenced Treatment Alternatives to Relieve Depression Data. Reviewed

Tada M, Uchida H, Suzuki T, Abe T, Pollock BG, Mimura M.

J Clin Psychopharmacol. 2014 Jun;34(3):297-302. doi: 10.1097/JCP.0000000000000112.   2014.6

Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. Reviewed

Takeuchi H, Fervaha G, Uchida H, Suzuki T, Bies RR, Grönte D, Remington G.

J Clin Psychiatry. 2014 May;75(5):506-11. doi: 10.4088/JCP.13m08695.   2014.3

Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. Reviewed

Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H.

Schizophr Res. 2014 Mar;153(1-3):184-8. doi: 10.1016/j.schres.2014.01.017.   2014.3

Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. Reviewed

Ishida T, Suzuki T, Watanabe K, Sakurai H, Uchida H, Mimura M.

Gen Hosp Psychiatry. 2014 Nov-Dec;36(6):690-3. doi: 10.1016/j.genhosppsych.2014.06.007.   2014

Effectiveness of saikokaryukotsuboreito (herbal medicine) for antipsychotic-induced sexual dysfunction in male patients with schizophrenia: a description of two cases. Reviewed

Takashi T, Uchida H, Suzuki T, Mimura M.

Case Rep Psychiatry. 2014;2014:784671. doi: 10.1155/2014/784671.   2014

Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data. Reviewed

Takeuchi H, Suzuki T, Bies RR, Remington G, Mamo DC, Pollock BG, Mimura M, Uchida H.

Schizophr Res. 2013 Nov;150(2-3):373-9. doi: 10.1016/j.schres.2013.08.033.   2013.11

Association between antidepressant side effects and functional impairment in patients with major depressive disorders. Reviewed

Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M.

Psychiatry Res. 2013 Nov 30;210(1):127-33. doi: 10.1016/j.psychres.2013.05.007.   2013.11

Trajectories of individual symptoms in remitters versus non-remitters with depression. Reviewed

Sakurai H, Uchida H, Abe T, Nakajima S, Suzuki T, Pollock BG, Sato Y, Mimura M.

J Affect Disord. 2013 Nov;151(2):506-13. doi: 10.1016/j.jad.2013.06.035.   2013.11

Effects of yoga therapy on postural stability in patients with schizophrenia-spectrum disorders: A single-blind randomized controlled trial. Reviewed

Ikai S, Uchida H, Suzuki T, Tsunoda K, Mimura M, Fujii Y.

J Psychiatr Res. 2013 Nov;47(11):1744-50. doi: 10.1016/j.jpsychires.2013.07.017.   2013.11

Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data. Reviewed

Moriguchi S, Bies RR, Remington G, Suzuki T, Mamo DC, Watanabe K, Mimura M, Pollock BG, Uchida H.

J Clin Psychopharmacol. 2013 Oct;33(5):682-5. doi: 10.1097/JCP.0b013e3182979a0a.   2013.10

Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Reviewed

Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H.

Schizophr Bull. 2013 Sep;39(5):993-8. doi: 10.1093/schbul/sbt090.   2013.9

Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. Reviewed

Uchida T, Suzuki T, Sakurai H, Tsutsumi C, Den R, Mimura M, Uchida H.

Int Clin Psychopharmacol. 2013 Sep;28(5):261-6. doi: 10.1097/YIC.0b013e328363aa5a.   2013.9

Absence of evidence that the pro re nata regimen confers benefit: a review of the studies.

Yoshida K, Suzuki T, Uchida H, Mimura M.

Int Clin Psychopharmacol. 2013 Sep;28(5):228-37. doi: 10.1097/YIC.0b013e328362db99.   2013.9

Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Reviewed

Tsuboi T, Bies RR, Suzuki T, Mamo DC, Pollock BG, Graff-Guerrero A, Mimura M, Uchida H.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:178-82. doi: 10.1016/j.pnpbp.2013.05.010.   2013.8

Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. Reviewed

Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, Deluca V, Ismail Z, Mamo D.

Psychopharmacology (Berl). 2013 Jul;228(1):43-51. doi: 10.1007/s00213-013-3012-1.   2013.6

Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Reviewed

Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H.

Schizophr Bull. 2013 May;39(3):564-74. doi: 10.1093/schbul/sbr189.   2013.5

Factor structure of the targeted inventory on problems in schizophrenia. Reviewed

Tanaka S, Nagase T, Suzuki T, Nomura K, Takeuchi H, Nakajima S, Uchida H, Yagi G, Watanabe K, Mimura M.

Clin Psychopharmacol Neurosci. 2013 Apr;11(1):18-23. doi: 10.9758/cpn.2013.11.1.18.   2013.4

Interventions to reduce antipsychotic polypharmacy: a systematic review. Reviewed

Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M.

Schizophr Res. 2013 Jan;143(1):215-20. doi: 10.1016/j.schres.2012.10.015.   2013.1

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Reviewed

Hirano J, Watanabe K, Suzuki T, Uchida H, Den R, Kishimoto T, Nagasawa T, Tomita Y, Hara K, Ochi H, Kobayashi Y, Ishii M, Fujita A, Kanai Y, Goto M, Hayashi H, Inamura K, Ooshima F, Sumida M, Ozawa T, Sekigawa K, Nagaoka M, Yoshimura K, Konishi M, Inagaki A, Saito T, Motohashi N, Mimura M, Okubo Y, Kato M.

Neuropsychiatr Dis Treat. 2013;9:1553-64. doi: 10.2147/NDT.S46108.   2013

Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature. Reviewed

Ikai S, Suzuki T, Uchida H, Mimura M, Fujii Y.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):e31. doi: 10.1345/aph.1S117.   2013

Oversight of constipation in inpatients with schizophrenia: a cross-sectional study. Reviewed

Koizumi T, Uchida H, Suzuki T, Sakurai H, Tsunoda K, Nishimoto M, Ishigaki T, Goto A, Mimura M.

Gen Hosp Psychiatry. 2013 Nov-Dec;35(6):649-52. doi: 10.1016/j.genhosppsych.2013.06.007.   2013

Coping strategies for antidepressant side effects: an Internet survey. Reviewed

Kikuchi T, Suzuki T, Uchida H, Watanabe K, Mimura M.

J Affect Disord. 2012 Dec 20;143(1-3):89-94. doi: 10.1016/j.jad.2012.04.039.   2012.12

Deficit status in bipolar disorder: investigation on prevalence rate and description of seven cases. Reviewed

Nio S, Suzuki T, Uchida H, Watanabe K, Mimura M.

J Affect Disord. 2012 Dec 20;143(1-3):248-52. doi: 10.1016/j.jad.2012.05.037.   2012.12

A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. Reviewed

Ikai S, Remington G, Suzuki T, Takeuchi H, Tsuboi T, Den R, Hirano J, Tsunoda K, Nishimoto M, Watanabe K, Mimura M, Mamo D, Uchida H.

J Clin Psychiatry. 2012 Aug;73(8):1147-52. doi: 10.4088/JCP.12m07638.   2012.8

Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey. Reviewed

Tani H, Uchida H, Suzuki T, Shibuya Y, Shimanuki H, Watanabe K, Den R, Nishimoto M, Hirano J, Takeuchi H, Nio S, Nakajima S, Kitahata R, Tsuboi T, Tsunoda K, Kikuchi T, Mimura M.

BMC Oral Health. 2012 Aug 18;12:32. doi: 10.1186/1472-6831-12-32.   2012.8

How psychotropic polypharmacy in schizophrenia begins: a longitudinal perspective. Reviewed

Shinfuku M, Uchida H, Tsutsumi C, Suzuki T, Watanabe K, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Mimura M, Kapur S.

Pharmacopsychiatry. 2012 Jun;45(4):133-7. doi: 10.1055/s-0031-1297934.   2012.6

Discontinuing donepezil or starting memantine for Alzheimer's disease.

Suzuki T.

N Engl J Med. 2012 Jun 7;366(23):2227-8; author reply 2228. doi: 10.1056/NEJMc1204656#SA1.   2012.6

Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Reviewed

Suzuki T, Remington G, Mulsant BH, Uchida H, Rajji TK, Graff-Guerrero A, Mimura M, Mamo DC.

Psychiatry Res. 2012 May 15;197(1-2):1-6. doi: 10.1016/j.psychres.2012.02.013.   2012.5

Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Reviewed

Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, Mimura M, Bies RR.

Ther Drug Monit. 2012 Apr;34(2):182-7. doi: 10.1097/FTD.0b013e3182489a6f.   2012.4

Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Reviewed

Mizuno Y, Bies RR, Remington G, Mamo DC, Suzuki T, Pollock BG, Tsuboi T, Watanabe K, Mimura M, Uchida H.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):182-7. doi: 10.1016/j.pnpbp.2011.12.013.   2012.4

Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. Reviewed

Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, Mimura M.

J Neurol Sci. 2012 Apr 15;315(1-2):137-40. doi: 10.1016/j.jns.2011.12.010.   2012.4

How successful are physicians in eliciting the truth from their patients? A large-scale Internet survey from patients' perspectives. Reviewed

Sawada N, Uchida H, Watanabe K, Kikuchi T, Suzuki T, Kashima H, Mimura M.

J Clin Psychiatry. 2012 Mar;73(3):311-7. doi: 10.4088/JCP.11m07078.   2012.3

Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Reviewed

Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M.

Schizophr Res. 2012 Feb;134(2-3):219-25. doi: 10.1016/j.schres.2011.11.021.   2012.2

Asymptomatic deep vein thrombosis in a patient with major depressive disorder. Reviewed

Ishida T, Katagiri T, Uchida H, Suzuki T, Watanabe K, Mimura M.

Case Rep Psychiatry. 2012;2012:261251. doi: 10.1155/2012/261251.   2012

Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Reviewed

Hazra M, Uchida H, Sproule B, Remington G, Suzuki T, Mamo DC.

Psychiatry Clin Neurosci. 2011 Dec;65(7):676-8. doi: 10.1111/j.1440-1819.2011.02280.x.   2011.12

Patient's trust in their psychiatrist: a cross-sectional survey. Reviewed

Minamisawa A, Suzuki T, Watanabe K, Imasaka Y, Kimura Y, Takeuchi H, Nakajima S, Kashima H, Uchida H.

Eur Arch Psychiatry Clin Neurosci. 2011 Dec;261(8):603-8. doi: 10.1007/s00406-011-0199-1.   2011.12

Subjective recognition of adverse events with antidepressant in people with depression: a prospective study. Reviewed

Kikuchi T, Suzuki T, Uchida H, Watanabe K, Kashima H.

J Affect Disord. 2011 Dec;135(1-3):347-53. doi: 10.1016/j.jad.2011.07.011.   2011.12

Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Reviewed

Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1983-9. doi: 10.1016/j.pnpbp.2011.08.008.   2011.12

Treatment resistant schizophrenia and response to antipsychotics: a review Reviewed

Suzuki T, Remington G, Mulsant BH, Rajji TK, Uchida H, Graff-Guerrero A, Mamo DC.

Schizophr Res. 2011 Dec;133(1-3):54-62. doi: 10.1016/j.schres.2011.09.016.   2011.12

Management of schizophrenia in late life with antipsychotic medications: a qualitative review Reviewed

Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC.

Drugs Aging. 2011 Dec 1;28(12):961-80. doi: 10.2165/11595830-000000000-00000.   2011.12

Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia

Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC.

Br J Psychiatry. 2011 Oct;199(4):275-80. doi: 10.1192/bjp.bp.110.083907.   2011.10

Plasma substance P level in patients with schizophrenia: a cross-sectional study. Reviewed

Ishida T, Uchida H, Suzuki T, Nakajima S, Watanabe K, Kashima H.

Psychiatry Clin Neurosci. 2011 Aug;65(5):526-8. doi: 10.1111/j.1440-1819.2011.02244.x.   2011.8

How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. Reviewed

Takeuchi H, Suzuki T, Uchida H, Kikuchi T, Nakajima S, Manki H, Watanabe K, Kashima H.

J Psychiatr Res. 2011 Aug;45(8):1083-8. doi: 10.1016/j.jpsychires.2011.01.007.   2011.8

The evolution of antipsychotic switch and polypharmacy in natural practice - a longitudinal perspective. Reviewed

Tsutsumi C, Uchida H, Suzuki T, Watanabe K, Takeuchi H, Nakajima S, Kimura Y, Tsutsumi Y, Ishii K, Imasaka Y, Kapur S.

Schizophr Res. 2011 Aug;130(1-3):40-6. doi: 10.1016/j.schres.2011.05.013.   2011.8

Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. Reviewed

Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC.

J Clin Psychopharmacol. 2011 Aug;31(4):497-502. doi: 10.1097/JCP.0b013e3182214aad.   2011.8

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Reviewed

Uchida H, Suzuki T, Takeuchi H, Arenovich T, Mamo DC.

Schizophr Bull. 2011 Jul;37(4):788-99. doi: 10.1093/schbul/sbp149.   2011.7

Metabolic syndrome in inpatients treated with clozapine.

Suzuki T.

J Clin Psychiatry. 2011 Jun;72(6):872-3; author reply 873-4. doi: 10.4088/JCP.11lr06864.   2011.6

A tipping point in drug dosing in late-life schizophrenia.

Tsuboi T, Suzuki T, Uchida H.

Curr Psychiatry Rep. 2011 Jun;13(3):225-33. doi: 10.1007/s11920-011-0189-z.   2011.6

Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. Reviewed

Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC.

J Clin Psychopharmacol. 2011 Jun;31(3):318-25. doi: 10.1097/JCP.0b013e318218d339.   2011.6

An importance of dose in antipsychotic combination therapy for schizophrenia.

Suzuki T.

J Clin Psychopharmacol. 2011 Jun;31(3):399; author reply 399-400. doi: 10.1097/JCP.0b013e318218f42a.   2011.6

Long-acting risperidone and oral antipsychotics in schizophrenia.

Suzuki T.

N Engl J Med. 2011 Jun 9;364(23):2265; author reply 265-6. doi: 10.1056/NEJMc1103917#SA2.   2011.6

Patients' attitudes toward side effects of antidepressants: an Internet survey. Reviewed

Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H.

Eur Arch Psychiatry Clin Neurosci. 2011 Mar;261(2):103-9. doi: 10.1007/s00406-010-0124-z.   2011.3

Clinical and demographic characteristics associated with postural instability in patients with schizophrenia. Reviewed

Koreki A, Tsunoda K, Suzuki T, Hirano J, Watanabe K, Kashima H, Uchida H.

J Clin Psychopharmacol. 2011 Feb;31(1):16-21. doi: 10.1097/JCP.0b013e318205e192.   2011.2

Risks of intermittent antipsychotic treatment in schizophrenia.

Suzuki T, Nomura K, Watanabe K.

J Clin Psychiatry. 2011 Jan;72(1):114; author reply 114-5. doi: 10.4088/JCP.10lr06452ye.   2011.1

Maternal depression and child development after prenatal DHA supplementation.

Suzuki T.

JAMA. 2011 Jan 26;305(4):359-60; author reply 360-1. doi: 10.1001/jama.2011.17.   2011.1

Factors associated with response to clozapine in schizophrenia: a review. Reviewed

Suzuki T, Uchida H, Watanabe K, Kashima H.

Psychopharmacol Bull. 2011;44(1):32-60.   2011

Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? Reviewed

Suzuki T.

Psychopharmacol Bull. 2011;44(1):18-31.   2011

Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Reviewed

Tsunoda K, Uchida H, Suzuki T, Watanabe K, Yamashima T, Kashima H.

Int J Geriatr Psychiatry. 2010 Dec;25(12):1259-65. doi: 10.1002/gps.2465.   2010.12

Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?

Suzuki T, Takeuchi H, Watanabe K.

J Clin Psychiatry. 2010 Nov;71(11):1553-4; author reply 1554. doi: 10.4088/JCP.10lr06261yel.   2010.11

Suzuki T, Takeuchi H, Nakajima S, Nomura K, Uchida H, Yagi G, Watanabe K, Kashima H. Reviewed

Magnitude of rater differences in assessment scales for schizophrenia.

J Clin Psychopharmacol. 2010 Oct;30(5):607-11. doi: 10.1097/JCP.0b013e3181f0bae1.   2010.10

Analysis of antipsychotic dose reduction.

Uchida H, Suzuki T, Takeuchi H, Mamo DC.

2010 Aug;167(8):994; author reply 994-5. doi: 10.1176/appi.ajp.2010.10030409.   2010.8

Depression severity and effect of antidepressant medications.

Suzuki T, Uchida H, Nakajima S.

JAMA. 2010 Apr 28;303(16):1597-8; author reply 1599. doi: 10.1001/jama.2010.507.   2010.4

Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Reviewed

Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):259-64. doi: 10.1016/j.pnpbp.2009.12.001.   2010.3

Sensitivity to antipsychotic drugs in older adults.

Leon C, Gerretsen P, Uchida H, Suzuki T, Rajji T, Mamo DC.

Curr Psychiatry Rep. 2010 Feb;12(1):28-33. doi: 10.1007/s11920-009-0080-3.   2010.2

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Reviewed

Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H.

Psychiatry Clin Neurosci. 2010 Feb;64(1):104-6. doi: 10.1111/j.1440-1819.2009.02036.x.   2010.2

Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Reviewed

Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, Yagi G, Watanabe K, Kashima H.

Hum Psychopharmacol. 2009 Dec;24(8):628-38. doi: 10.1002/hup.1073.   2009.12

Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review. Reviewed

Nakajima S, Ishida T, Akaishi R, Takahata K, Kitahata R, Uchida H, Suzuki T, Takeuchi H, Nomura K, Nakagawa A, Watanabe K, Kashima H.

J ECT. 2009 Sep;25(3):178-81. doi: 10.1097/YCT.0b013e3181a8e2ac.   2009.9

Selective serotonin reuptake inhibitor-induced spermatorrhea in 2 patients. Reviewed

Nakajima S, Uchida H, Suzuki T, Watanabe K, Kashima H.

J Clin Psychiatry. 2009 Aug;70(8):1192-3. doi: 10.4088/JCP.09l05007.   2009.8

Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. Reviewed

Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H.

J Clin Psychopharmacol. 2009 Aug;29(4):394-5. doi: 10.1097/JCP.0b013e3181accfec.   2009.8

Persistence and compliance to antidepressant treatment in patients with depression: a chart review. Reviewed

Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, Kashima H.

BMC Psychiatry. 2009 Jun 16;9:38. doi: 10.1186/1471-244X-9-38.   2009.6

Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. Reviewed

Uchida H, Suzuki T, Mamo DC, Mulsant BH, Kikuchi T, Takeuchi H, Tomita M, Watanabe K, Yagi G, Kashima H.

J Anxiety Disord. 2009 May;23(4):477-81. doi: 10.1016/j.janxdis.2008.10.003.   2009.5

Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Reviewed

Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tsunoda K, Takeuchi H, Kikuchi T, Nakajima S, Nomura K, Tomita M, Watanabe K, Kashima H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):244-6. doi: 10.1111/j.1440-1819.2008.01920.x.   2009.4

Should adjunctive antipsychotic treatment be continued in remitted patients with depression? Reviewed

Uchida H, Suzuki T, Watanabe K, Kashima H.

Psychiatry Clin Neurosci. 2009 Feb;63(1):126. doi: 10.1111/j.1440-1819.2008.01897.x.   2009.2

Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder. Reviewed

Nakajima S, Suzuki T, Uchida H, Watanabe K, Kashima H.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):160-1. doi: 10.1016/j.pnpbp.2008.10.021.   2009.2

Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Reviewed

Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, Yagi G, Watanabe K, Kashima H.

Schizophr Res. 2008 Dec;106(2-3):328-36. doi: 10.1016/j.schres.2008.08.013.   2008.12

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Reviewed

Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, Manki H, Watanabe K, Kashima H.

J Clin Psychopharmacol. 2008 Oct;28(5):540-3. doi: 10.1097/JCP.0b013e3181842586.   2008.10

Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Reviewed

Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, Tanabe A, Yagi G, Kashima H.

Hum Psychopharmacol. 2008 Aug;23(6):455-63. doi: 10.1002/hup.959.   2008.8

Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Reviewed

Uchida H, Suzuki T, Mamo DC, Mulsant BH, Tanabe A, Inagaki A, Watanabe K, Yagi G, Tomita M.

Am J Geriatr Psychiatry. 2008 Jul;16(7):584-93. doi: 10.1097/JGP.0b013e318172b42d.   2008.7

A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication. Reviewed

Suzuki T, Uchida H, Watanabe K, Kashima H.

Psychopharmacol Bull. 2008;41(1):164-70.   2008.1

Treatment target in schizophrenia: a critical review and a clinical suggestion. Reviewed

Suzuki T, Uchida H, Watanabe K, Kashima H.

Psychopharmacol Bull. 2008;41(4):80-102.   2008

How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Reviewed

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H.

Psychopharmacology (Berl). 2007 Dec;195(2):285-95.   2007.12

Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. Reviewed

Suzuki T, Uchida H, Watanabe K, Kashima H.

J Clin Pharm Ther. 2007 Oct;32(5):525-7.   2007.10

An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia. Reviewed

Nakajima S, Uchida H, Suzuki T, Tomita M, Tsunoda K, Kitta M, Takeuchi H, Nomura K, Watanabe K, Kashima H.

J Clin Psychopharmacol. 2007 Aug;27(4):401-3.   2007.8

Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. Reviewed

Suzuki T, Uchida H, Watanabe K, Kashima H.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1141-2.   2007.6

Antipsychotics-induced hypersensitivity of visual perception. Reviewed

Uchida H, Suzuki T, Watanabe K, Kashima H.

Eur Psychiatry. 2006 Jul;21(5):343-4.   2006.7

Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect. Reviewed

Uchida H, Suzuki T, Yamazawa R, Tomita M, Nemoto T, Kimura Y, Watanabe K, Imasaka Y, Kashima H.

J Clin Psychopharmacol. 2006 Feb;26(1):50-5.   2006.2

Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. Reviewed

Uchida H, Takeuchi H, Suzuki T, Nomura K, Watanabe K, Kashima H.

J Clin Psychopharmacol. 2005 Dec;25(6):545-51.   2005.12

Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Reviewed

Suzuki T, Uchida H, Takeuchi H, Nomura K, Tanabe A, Watanabe K, Yagi G, Kashima H.

Psychopharmacology (Berl). 2005 Sep;181(3):566-75.   2005.9

Two case reports of successful prevention of overdosing in borderline patients. Reviewed

Uchida H, Watanabe K, Suzuki T, Goto A, Kashima H.

Psychiatry. 2005;68(2):179-82.   2005

Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Reviewed

Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H.

Int J Neuropsychopharmacol. 2004 Jun;7(2):133-42.   2004.6

A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Reviewed

Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):361-9.   2004.3

Antipsychotic-induced paroxysmal perceptual alteration. Reviewed

Uchida H, Suzuki T, Watanabe K, Yagi G, Kashima H.

Am J Psychiatry. 2003 Dec;160(12):2243-4.   2003.12

Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Reviewed

Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H.

Int Clin Psychopharmacol. 2003 Nov;18(6):323-9.   2003.11

Recurrent episodes of perceptual alteration in patients treated with antipsychotic agents. Reviewed

Uchida H, Suzuki T, Tanaka KF, Watanabe K, Yagi G, Kashima H.

J Clin Psychopharmacol. 2003 Oct;23(5):496-9.   2003.10